When Outcomes Matter, Choose MTF Biologics 

CONMED is the exclusive representative of MTF Biologics’ sports medicine allografts. In addition to safely placing over 9 million allografts, studies have shown that allograft tissue processed using similar methods as MTF Biologics was found to have lower revision rates than allografts using processing methods of other tissue banks.1

Better Outcomes Start

with Better Processing 

In an independent study of 9,458 ACL Reconstructions,1 it was found that allografts from tissue banks that highly process their grafts with harsh chemicals and terminal radiation increase the risk of revision surgery. Mechanical testing has also shown that terminally radiated allografts demonstrate increased creep (elongation) and decreased dynamic stiffness.2

Our exclusive tissue bank partner MTF Biologics has placed more than 9 million allografts with zero disease transmissions, delivering on the promise of the highest quality tissue and outcomes for your patients.2 MTF Biologics has been processing and distributing allografts for over 30 years.


MTF Biologics never uses H2O2, harmful chemicals or terminal radiation during allograft processing. Instead, they minimally process donor tissue to help preserve the allograft’s natural biomechanical and healing properties.

Our exclusive tissue bank partner MTF Biologics maintains the most stringent donor screening process of any tissue bank – exceeding the industry standards all tissue banks must follow. In fact, MTF Biologics accepts less than 3% of the potential donor referrals they receive.

Experience the Difference. Try MTF Biologics in your Next Case. 

References:

1Maletis, Gregory, et al. “Increased Risk of Revision after ACLR with Soft Tissue Allograft Compared to Hamstring Autograft.” ISAKOS. 6 June 2015. ePoster #1219. 1

2Data on File, MTF

3Stoker et al. “Chondrocyte Viability at Time of Transplantation for Osteochondral Allografts Preserved by the Missouri Osteochondral Preservation System versus Standard Tissue Bank Protocol.” Journal of Knee Surgery. Volume 31, Issue 8, pp. 772-780, September 2018

Careers        Investors        Contact Us        Legal and Privacy                       

© Copyright 2020 CONMED Corporation. All Rights Reserved. 

No Terminal Radiation
No Harsh Chemicals

2.0%

< 1.8 Mrad

3.2%

w/chemical processing

H2O2 & Alcohol

5.3%

> 1.8 Mrad

6.8%

w/chemical processing

Lower Revision Rates

Safely Distributed Over 9 Million Allografts

Minimally Invasive Processing

Stringent Donor Screening

Learn more about MTF Products

Available exclusively from CONMED through MTF Biologics, osteochondral allografts with the Missouri Osteochondral Preservation System (MOPS℠) provide nearly double the storage-life with increased viable chondrocyte density.3 

Extend Osteochondral Allograft Shelf Life With MOPS3 

Expansive Offering of Sports Medicine Allografts 

Our portfolio of solutions includes soft tissue allografts with and without bone blocks for primary or revision reconstructive surgeries; osteochondral allografts and instrumentation for cartilage repair; and meniscal allografts for subtotal or total meniscectomy, glenoid resurfacing, and interpositional arthroplasty.  

Learn MoreFull PortfolioDownload Catalog
Try MTF

When Outcomes Matter, Choose MTF Biologics 

CONMED is the exclusive representative of MTF Biologics’ sports medicine allografts. In addition to safely placing over 9 million allografts, studies have shown that allograft tissue processed using similar methods as MTF Biologics was found to have lower revision rates than allografts using processing methods of other tissue banks.1

Better Outcomes Start

with Better Processing 

Lower Revision Rates

In an independent study of 9,458 ACL Reconstructions,1 it was found that allografts from tissue banks that highly process their grafts with harsh chemicals and terminal radiation increase the risk of revision surgery. Mechanical testing has also shown that terminally radiated allografts demonstrate increased creep (elongation) and decreased dynamic stiffness.2

No Terminal Radiation
No Harsh Chemicals

2.0%

< 1.8 Mrad

3.2%

w/chemical processing

H2O2 & Alcohol

5.3%

> 1.8 Mrad

6.8%

w/chemical processing

Safely Distributed Over 9 Million Allografts

Our exclusive tissue bank partner MTF Biologics has placed more than 9 million allografts with zero disease transmissions, delivering on the promise of the highest quality tissue and outcomes for your patients.2 MTF Biologics has been processing and distributing allografts for over 30 years.


Minimally Invasive Processing

MTF Biologics never uses H2O2, harmful chemicals or terminal radiation during allograft processing. Instead, they minimally process donor tissue to help preserve the allograft’s natural biomechanical and healing properties.

Learn more about MTF Products

Stringent Donor Screening

Our exclusive tissue bank partner MTF Biologics maintains the most stringent donor screening process of any tissue bank – exceeding the industry standards all tissue banks must follow. In fact, MTF Biologics accepts less than 3% of the potential donor referrals they receive.

Extend Osteochondral Allograft Shelf Life With MOPS3 

Available exclusively from CONMED through MTF Biologics, osteochondral allografts with the Missouri Osteochondral Preservation System (MOPS℠) provide nearly double the storage-life with increased viable chondrocyte density.3 

Learn More

Expansive Offering of Sports Medicine Allografts

Our portfolio of solutions includes soft tissue allografts with and without bone blocks for primary or revision reconstructive surgeries; osteochondral allografts and instrumentation for cartilage repair; and meniscal allografts for subtotal or total meniscectomy, glenoid resurfacing, and interpositional arthroplasty.  

Full PortfolioDownload Catalog

Experience the Difference. Try MTF Biologics in your Next Case. 

References:

1Maletis, Gregory, et al. “Increased Risk of Revision after ACLR with Soft Tissue Allograft Compared to Hamstring Autograft.” ISAKOS. 6 June 2015. ePoster #1219. 1

2Data on File, MTF

3Stoker et al. “Chondrocyte Viability at Time of Transplantation for Osteochondral Allografts Preserved by the Missouri Osteochondral Preservation System versus Standard Tissue Bank Protocol.” Journal of Knee Surgery. Volume 31, Issue 8, pp. 772-780, September 2018 

Careers
Investors
Contact Us 
Legal and Privacy                       

© Copyright 2019 CONMED Corporation. All Rights Reserved.